Search

Your search keyword '"Zignego AL."' showing total 360 results
Start Over Author "Zignego AL."
360 results on '"Zignego AL."'

2. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

Author

Aghemo, A, Alberti, A, Andreone, P, Angelico, M, Brunetto, Mr, Chessa, L, Ciancio, A, Craxì, A, Gaeta, Gb, Galli, M, Gasbarrini, A, Giorgini, A, Grilli, E, Lampertico, P, Lichtner, M, Milella, M, Morisco, F, Persico, M, Pirisi, M, Puoti, M, Raimondo, G, Romano, A, Russello, M, Sangiovanni, V, Schiavini, M, Serviddio, G, Villa, E, Vinci, M, De Michina, A, Gallinaro, V, Gualberti, G, Roscini, As, Zignego, Al, MARS Study Group, Aghemo A., Alberti A., Andreone P., Angelico M., Brunetto M.R., Chessa L., Ciancio A., Craxi A., Gaeta G.B., Galli M., Gasbarrini A., Giorgini A., Grilli E., Lampertico P., Lichtner M., Milella M., Morisco F., Persico M., Pirisi M., Puoti M., Raimondo G., Romano A., Russello M., Sangiovanni V., Schiavini M., Serviddio G., Villa E., Vinci M., De Michina A., Gallinaro V., Gualberti G., Roscini A.S., Zignego A.L., Aghemo, A, Alberti, A, Andreone, P, Angelico, M, Brunetto, M, Chessa, L, Ciancio, A, Craxi, A, Gaeta, G, Galli, M, Gasbarrini, A, Giorgini, A, Grilli, E, Lampertico, P, Lichtner, M, Milella, M, Morisco, F, Persico, M, Pirisi, M, Puoti, M, Raimondo, G, Romano, A, Russello, M, Sangiovanni, V, Schiavini, M, Serviddio, G, Villa, E, Vinci, M, De Michina, A, Gallinaro, V, Gualberti, G, Roscini, A, Zignego, A, Aghemo, A., Alberti, A., Andreone, P., Angelico, M., Brunetto, M. R., Chessa, L., Ciancio, A., Craxi, A., Gaeta, G. B., Galli, M., Gasbarrini, A., Giorgini, A., Grilli, E., Lampertico, P., Lichtner, M., Milella, M., Morisco, F., Persico, M., Pirisi, M., Puoti, M., Raimondo, G., Romano, A., Russello, M., Sangiovanni, V., Schiavini, M., Serviddio, G., Villa, E., Vinci, M., De Michina, A., Gallinaro, V., Gualberti, G., Roscini, A. S., and Zignego, A. L.

Subjects
Male, Adult, medicine.medical_specialty, Pyrrolidines, Quinoxaline, Sustained Virologic Response, Settore MED/12 - GASTROENTEROLOGIA, Population, Antiviral Agents, elderly, Benzimidazole, GLE/PIB, Quinoxalines, Internal medicine, Drug Combination, Clinical endpoint, medicine, Product Surveillance, Postmarketing, Humans, Prospective Studies, education, Adverse effect, Aged, Antiviral Agent, Sulfonamides, education.field_of_study, Hepatology, business.industry, Settore MED/09 - MEDICINA INTERNA, Gastroenterology, PWUD, Glecaprevir, Middle Aged, HCV, Hepatitis C, Chronic, Pibrentasvir, Discontinuation, Drug Combinations, Italy, Cohort, Quality of Life, Benzimidazoles, Female, Observational study, business
Abstract

Background and Aims The MARS post-marketing, observational study evaluates glecaprevir/pibrentasvir in a large population of Italian patients who are infected with HCV. Patients and Methods Achievement of SVR12 was the primary endpoint in the overall population and by subpopulations of interest (treatment-naive and treatment-experienced patients, subjects infected with different HCV genotype/sub-genotype, cirrhotic and non-cirrhotic patients, patients with different severity of fibrosis, patients with an APRI score ≥1, subjects with comorbidities, HIV-coinfected patients, elderly patients and people who use drugs). Safety and quality of life (assessed by SF-36 and Work Productivity and Activity Impairment) were also evaluated. Results The SVR12 rate was 99.4% (319/321; 95% CI: 97.8–99.8%) in the core population with sufficient follow-up (n = 321), 99.7% (289/290) in 8-week treated patients, and high (>96%) across subgroups. Only three patients (0.9%) had treatment-related adverse events that led to treatment discontinuation. In total, 30.1% of patients showed an improvement of ≥2.5 points in the Physical Component Summary of the SF-36 from baseline to the end of treatment, and this figure raised to 37.5% with the achievement of SVR12. Corresponding values for MCS were 42.2% and 42.8%, respectively. Conclusion Glecaprevir/pibrentasvir is safe and effective across subpopulations who are underserved in clinical trials.

Published
2021

4. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Author

Kondili, La, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, Al, Brunetto, Mr, Raimondo, G, Taliani, G, Iannone, A, Russo, Fp, Santantonio, Ta, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, Em, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, Mg, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, Mg, Montilla, S, Razavi, H, Melazzini, M, Vella, S, Craxì, A, PITER Collaborating, Group., Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì Antonio, Kondili, Loreta A., Robbins, Sarah, Blach, Sarah, Gamkrelidze, Ivane, Zignego, Anna L., Brunetto, Maurizia R., Raimondo, Giovanni, Taliani, Gloria, Iannone, Andrea, Russo, Francesco P., Santantonio, Teresa A., Zuin, Massimo, Chessa, Luchino, Blanc, Pierluigi, Puoti, Massimo, Vinci, Maria, Erne, Elke M., Strazzabosco, Mario, Massari, Marco, Lampertico, Pietro, Rumi, Maria G., Federico, Alessandro, Orlandini, Alessandra, Ciancio, Alessia, Borgia, Guglielmo, Andreone, Pietro, Caporaso, Nicola, Persico, Marcello, Ieluzzi, Donatella, Madonia, Salvatore, Gori, Andrea, Gasbarrini, Antonio, Coppola, Carmine, Brancaccio, Giuseppina, Andriulli, Angelo, Quaranta, Maria G., Montilla, Simona, Razavi, Homie, Melazzini, Mario, Vella, Stefano, Craxì, Antonio, Kondili, L. A., Robbins, S., Blach, S., Gamkrelidze, I., Zignego, A. L., Brunetto, M. R., Raimondo, G., Taliani, G., Iannone, A., Russo, F. P., Santantonio, T. A., Zuin, M., Chessa, L., Blanc, P., Puoti, M., Vinci, M., Erne, E. M., Strazzabosco, M., Massari, M., Lampertico, P., Rumi, M. G., Federico, A., Orlandini, A., Ciancio, A., Borgia, G., Andreone, P., Caporaso, N., Persico, M., Ieluzzi, D., Madonia, S., Gori, A., Gasbarrini, A., Coppola, C., Brancaccio, G., Andriulli, A., Quaranta, M. G., Montilla, S., Razavi, H., Melazzini, M., Vella, S., Craxi, A., Kondili, L, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, A, Brunetto, M, Raimondo, G, Taliani, G, Iannone, A, Russo, F, Santantonio, T, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, E, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, M, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, M, Montilla, S, Razavi, H, Melazzini, M, Vella, S, and Craxi, A

Subjects
HCV, WHO, chronic infection, linkage to care, Liver Cirrhosis, medicine.medical_specialty, Carcinoma, Hepatocellular, Sustained Virologic Response, Viral Hepatitis, Settore MED/12 - GASTROENTEROLOGIA, World Health Organization, Antiviral Agents, NO, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Pharmacotherapy, Cost of Illness, Cause of Death, Health care, medicine, Humans, 030212 general & internal medicine, Viremia, chronic infection, HCV, linkage to care, WHO, Disease Eradication, Mortality, Intensive care medicine, Cause of death, Hepatology, business.industry, Public health, Carcinoma, Liver Neoplasms, Hepatocellular, Hepatitis C, medicine.disease, Markov Chains, Italy, 030211 gastroenterology & hepatology, business, Viral hepatitis
Abstract

Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat will be depleted by 2025. Increased case finding through a targeted screening strategy in 1948‐1978 birth cohorts could supplement the pool of diagnosed patients by finding 75% of F0‐F3 cases. Under the 60% linked‐to‐care scenario, viraemic infections would decline by 70% by 2030 but the patients eligible for treatment will run out by 2028. If treatment is to be maintained, a screening strategy focusing on 1958‐1978 birth cohorts could capture 55% of F0‐F3 individuals. Under the 80% linked‐to‐care scenario, screening limited in 1968‐1978 birth cohorts could sustain treatment at levels required to achieve the HCV elimination goals. Conclusion In Italy, which is an HCV endemic country, the eligible pool of patients to treat will run out between 2025 and 2028. To maintain the treatment rate and achieve the HCV elimination goals, increased case finding in targeted, high prevalence groups is required.

Published
2018

5. AISF position paper on HCV in immunocompromised patients

Author

Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Brunetto, MR, Cabras, MG, Clemente, MG, Ditto, MC, Gaeta, GB, Grossi, PA, Macaluso, FS, Zignego, AL, Giannini, EG, Russo, FP, Valle, RD, Peroni, CL, Saracco, GM, Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Brunetto, MR, Cabras, MG, Clemente, MG, Ditto, MC, Gaeta, GB, Grossi, PA, Macaluso, FS, Zignego, AL, Giannini, EG, Russo, FP, Valle, RD, Peroni, CL, and Saracco, GM

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Published
2019

6. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

Author

Burra, P, Rodríguez-Castro, K, Guarino, M, Morisco, F, Villa, E, Mazzella, G, Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) (Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, Giulia, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al), Alisi A, Balsano C, Bernabucci V, Berzigotti A, Brunetto M, Bugianesi E, Burra P, Calvaruso V, Cariani E, Coco B, Colle I, Critelli R, De Martin E, Del Buono M, Fabregat I, Faillaci F, Fattovich G, Floreani A, Garcia-Tsao G, Housset C, Karampatou A, Lei B, Mangia A, Martinez-Chantar ML, Milosa F, Morisco F, Nasta P, Ozben T, Pollicino T, Ponti ML, Pontisso P, Reeves H, Rendina M, Rodríguez-Castro KI, Sagnelli C, Sebastiani G, Smedile A, Taliani G, Vandelli C, Vanni E, Villa E, Vukotic R, Zignego AL, Burra P, Rodríguez-Castro K, Guarino M, Morisco F, Villa E, Mazzella G., Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Burra, P, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Morisco, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, G, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al, Rodríguez-Castro, K, Guarino, M, Villa, E, Mazzella, G., Garcia Tsao, G, Martinez Chantar, Ml, Morisco, Filomena, Rodríguez Castro, Ki, Rodríguez Castro, K, Guarino, Maria, Alisi, Anna, Balsano, Clara, Bernabucci, Veronica, Berzigotti, Annalisa, Brunetto, Maurizia, Bugianesi, Elisabetta, Burra, Patrizia, Calvaruso, Vincenza, Cariani, Elisabetta, Coco, Barbara, Colle, Isabelle, Critelli, Rosina, De Martin, Eleonora, Del Buono, Mariagrazia, Fabregat, Isabel, Faillaci, Francesca, Fattovich, Giovanna, Floreani, Annarosa, Garcia-tsao, Guadalupe, Housset, Chantal, Karampatou, Aimilia, Lei, Barbara, Mangia, Alessandra, Martinez-chantar, Maria Luz, Milosa, Fabiola, Nasta, Paola, Ozben, Tomri, Pollicino, Teresa, Ponti, Maria Laura, Pontisso, Patrizia, Reeves, Helen, Rendina, Maria, Rodrã­guez-castro, Kryssia Isabel, Sagnelli, Caterina, Sebastiani, Giada, Smedile, Antonella, Taliani, Gloria, Vandelli, Carmen, Vanni, Ester, Villa, Erica, Vukotic, Ranka, Zignego, Anna Linda, Rodrã­guez-castro, Kryssia, and Mazzella, Giuseppe

Subjects
Risk Assessment, Fertility, Immunosuppression, Liver transplantation, Pregnancy, Immunosuppressive Agent, Medical, Hepatology, Gastroenterology, Humans, Obstetric Labor Complication, Societies, Medical, Postpartum Period, Pregnancy Outcome, Contraception, Female, Italy, Obstetric Labor Complications, Practice Guidelines as Topic, Pregnancy Complications, Immunosuppressive Agents, Liver Transplantation, Pregnancy Complication, surgical procedures, operative, Societies, Human
Abstract

After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paediatricians, and transplant hepatologists ever more frequently encounter such patients. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, foetal growth restriction, and gestational diabetes, which, by definition, render pregnancy in liver transplant recipients a high-risk one. In contrast, the risk of congenital anomalies and the live birth rate are comparable to those of the general population. Currently there are still no robust guidelines on the management of pregnancies after liver transplantation. The aim of this position paper is to review the available evidence on pregnancy in liver transplant recipients and to provide national Italian recommendations for clinicians caring for these patients. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Published
2016

7. PITER collaborating group. Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals?

Author

Kondili, La, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, Al, Brunetto, Mr, Raimondo, G, Taliani, G, Iannone, A, Russo, Fp, Santantonio, Ta, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, Em, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, Mg, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, Mg, Montilla, S, Razavi, H, Melazzini, M, Vella, S, and Craxì, A

Published
2018

9. IgG cryoglobulinemia

Author

Gulli, F, Basile, U, Gragnani, L, Napodano, C, Pocino, K, Miele, L, Santini, Sa, Zignego, Al, Gasbarrini, A, and Rapaccini, Gl

Subjects
Male, Hepatitis C Virus, Settore MED/12 - GASTROENTEROLOGIA, IgG3, Cryoglobulin, IgG3, Hepatitis C Virus, Cryoglobulin, Peripheral Nervous System Diseases, Middle Aged, Hepatitis C, Cryoglobulinemia, Blood-Brain Barrier, Rheumatoid Factor, Immunoglobulin G, inglese, Humans, Female, Aged
Abstract

Mixed Cryoglobulinemia is the most well-known Hepatitis C Virus (HCV)-associated extrahepatic manifestation. MC is both an autoimmune and B-lymphoproliferative disorder. Cryoglobulins (CGs) are classified into three groups according to immunoglobulin (Ig) composition: type I is composed of one isotype or Ig class. Type II and type III mixed CGs are immune complexes composed of polyclonal IgGs acting as autoantigens and mono, polyclonal or oligoclonal IgM with rheumatoid factor activity. IgG1 and IgG3 are the predominant subclasses involved. This study shows the simultaneous presence of IgG-RF and IgG3, supporting the hypothesis of an involvement of this subclass in the initiation of early stages of CGs.We describe a case series of six HCV-positive patients, all of whom had peripheral neuropathy and transient ischemic attacks, presenting cryoprecipitates formed by IgG3 and IgG1. Cryoprecipitate IgG subclass research was carried out by immunofixation electrophoresis by using antisera against IgG1, IgG2, IgG3, and IgG4.Our six patients presented with an immunochemical pattern characterized by the mere presence of IgG1 and IgG3 subclasses with probable RF activity and one of these six patients exhibited monoclonal IgG3 in his cerebrospinal fluid.We can hypothesize that the IgG passage through the blood-brain barrier could have contributed to the cause of TIAs, through a mechanism involving the precipitation of circulating immune complexes formed by the two subclasses in the intrathecal vessels.

Published
2018

10. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement

Author

Zignego, Al, Ramos-Casals, M, Ferri, C, Saadoun, D, Arcaini, L, Roccatello, D, Antonelli, A, Desbois, Ac, Comarmond, C, Gragnani, L, Casato, M, Lamprecht, P, Mangia, A, Tzioufas, Ag, Younossi, Zm, Cacoub, P, and De Santis, A.

Subjects
medicine.medical_specialty, Health Planning Guidelines, SF-36, Non-etiological therapy, Hepatitis C virus, Immunology, Hepacivirus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Multidisciplinary approach, medicine, Humans, Immunology and Allergy, Anti-HCV therapy, Intensive care medicine, Cryoglobulinemic vasculitis, Extrahepatic manifestations of HCV, Hepatitis C virus (HCV), business.industry, virus diseases, medicine.disease, Hepatitis C, digestive system diseases, Lymphoma, 030220 oncology & carcinogenesis, Etiology, 030211 gastroenterology & hepatology, business
Abstract

Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.

Published
2017

11. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

Author

Kondili, La, Romano, F, Rolli, Fr, Ruggeri, M, Rosato, S, Brunetto, Mr, Zignego, Al, Ciancio, A, Di Leo, A, Raimondo, G, Ferrari, C, Taliani, G, Borgia, G, Santantonio, Ta, Blanc, P, Gaeta, Gb, Gasbarrini, A, Chessa, L, Erne, Em, Villa, E, Ieluzzi, D, Russo, Fp, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Puoti, M, Alberti, A, Nardone, G, Massari, M, Montalto, G, Foti, G, Rumi, Mg, Quaranta, Mg, Cicchetti, A, Craxì, A, Vella, S, PITER Collaborating Group, Kondili, Loreta A., Romano, Federica, Rolli, Francesca Romana, Ruggeri, Matteo, Rosato, Stefano, Brunetto, Maurizia Rossana, Zignego, Anna Linda, Ciancio, Alessia, Di Leo, Alfredo, Raimondo, Giovanni, Ferrari, Carlo, Taliani, Gloria, Borgia, Guglielmo, Santantonio, Teresa Antonia, Blanc, Pierluigi, Gaeta, Giovanni Battista, Gasbarrini, Antonio, Chessa, Luchino, Erne, Elke Maria, Villa, Erica, Ieluzzi, Donatella, Russo, Francesco Paolo, Andreone, Pietro, Vinci, Maria, Coppola, Carmine, Chemello, Liliana, Madonia, Salvatore, Verucchi, Gabriella, Persico, Marcello, Zuin, Massimo, Puoti, Massimo, Alberti, Alfredo, Nardone, Gerardo, Massari, Marco, Montalto, Giuseppe, Foti, Giuseppe, Rumi, Maria Grazia, Quaranta, Maria Giovanna, Cicchetti, Americo, Craxì, Antonio, Vella, Stefano, Kondili, L, Romano, F, Rolli, F, Ruggeri, M, Rosato, S, Brunetto, M, Zignego, A, Ciancio, A, Di Leo, A, Raimondo, G, Ferrari, C, Taliani, G, Borgia, G, Santantonio, T, Blanc, P, Gaeta, G, Gasbarrini, A, Chessa, L, Erne, E, Villa, E, Ieluzzi, D, Russo, F, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Puoti, M, Alberti, A, Nardone, G, Massari, M, Montalto, G, Foti, G, Rumi, M, Quaranta, M, Cicchetti, A, Craxì, A, Vella, S, Kondili LA1, Romano F2, Rolli FR2, Ruggeri M2, Rosato S1, Brunetto MR3, Zignego AL4, Ciancio A5, Di Leo A6, Raimondo G7, Ferrari C8, Taliani G9, Borgia G10, Santantonio TA11, Blanc P12, Gaeta GB13, Gasbarrini A2, Chessa L14, Erne EM15, Villa E16, Ieluzzi D17, Russo FP15, Andreone P18, Vinci M19, Coppola C20, Chemello L15, Madonia S21, Verucchi G18, Persico M22, Zuin M23, Puoti M19, Alberti A15, Nardone G13, Massari M24, Montalto G25, Foti G26, Rumi MG23, Quaranta MG1, Cicchetti A2, Craxì Antonio, Vella S1, and PITER Collaborating Group.

Subjects
hepatitis C virus, Pediatrics, Cost effectiveness, Viral Hepatitis, Adult, Aged, Aged, 80 and over, Antiviral Agents, Cohort Studies, Cost-Benefit Analysis, Health Policy, Hepatitis C, Humans, Middle Aged, Young Adult, Models, Economic, Hepatology, Direct-acting antiviral, Liver disease, 0302 clinical medicine, Models, Health care, antiviral therapy, 80 and over, incremental cost-effectiveness ratio, health care economics and organizations, HCV cost -effectiveness, Direct-acting antiviral, hepatocellular carcinoma, hepatitis C virus, incremental cost-effectiveness ratio, interferon, quality-adjusted life-years, sustained virological response, willingness to pay, Cost–benefit analysis, 030503 health policy & services, quality-adjusted life-years, hepatocellular carcinoma, interferon, HCV, cost-effectiveness, real-life cohort, Cohort, 030211 gastroenterology & hepatology, Original Article, sustained virological response, 0305 other medical science, Cohort study, Human, medicine.medical_specialty, Economic, NO, 03 medical and health sciences, medicine, Cost-Benefit Analysi, Health policy, Antiviral Agent, business.industry, Original Articles, medicine.disease, Surgery, Cohort Studie, business, willingness to pay
Abstract

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies’ cost-effectiveness. The patients’ age and fibrosis stage, assumed DAA treatment cost of €15,000/patient, and the Italian liver disease costs were used to evaluate quality-adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER) of policy 1 versus policy 2. To generalize the results, a European scenario analysis was performed, resampling the study population, using the mean European country-specific health states costs and mean treatment cost of €30,000. For the Italian base-case analysis, the cost-effective ICER obtained using policy 1 was €8,775/QALY. ICERs remained cost-effective in 94%-97% of the 10,000 probabilistic simulations. For the European treatment scenario the ICER obtained using policy 1 was €19,541.75/QALY. ICER was sensitive to variations in DAA costs, in the utility value of patients in fibrosis stages F0-F3 post–sustained virological response, and in the transition probabilities from F0 to F3. The ICERs decrease with decreasing DAA prices, becoming cost-saving for the base price (€15,000) discounts of at least 75% applied in patients with F0-F2 fibrosis. Conclusion: Extending hepatitis C virus treatment to patients in any fibrosis stage improves health outcomes and is cost-effective; cost-effectiveness significantly increases when lowering treatment prices in early fibrosis stages. (Hepatology 2017;66:1814–1825).

Published
2017

12. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

Author

Kondili, L, Romano, F, Rolli, F, Ruggeri, M, Rosato, S, Brunetto, M, Zignego, A, Ciancio, A, Di Leo, A, Raimondo, G, Ferrari, C, Taliani, G, Borgia, G, Santantonio, T, Blanc, P, Gaeta, G, Gasbarrini, A, Chessa, L, Erne, E, Villa, E, Ieluzzi, D, Russo, F, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Puoti, M, Alberti, A, Nardone, G, Massari, M, Montalto, G, Foti, G, Rumi, M, Quaranta, M, Cicchetti, A, Craxì, A, Vella, S, Kondili, LA, Rolli, FR, Brunetto, MR, Zignego, AL, Santantonio, TA, Gaeta, GB, Erne, EM, Russo, FP, Rumi, MG, Quaranta, MG, Kondili, L, Romano, F, Rolli, F, Ruggeri, M, Rosato, S, Brunetto, M, Zignego, A, Ciancio, A, Di Leo, A, Raimondo, G, Ferrari, C, Taliani, G, Borgia, G, Santantonio, T, Blanc, P, Gaeta, G, Gasbarrini, A, Chessa, L, Erne, E, Villa, E, Ieluzzi, D, Russo, F, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Puoti, M, Alberti, A, Nardone, G, Massari, M, Montalto, G, Foti, G, Rumi, M, Quaranta, M, Cicchetti, A, Craxì, A, Vella, S, Kondili, LA, Rolli, FR, Brunetto, MR, Zignego, AL, Santantonio, TA, Gaeta, GB, Erne, EM, Russo, FP, Rumi, MG, and Quaranta, MG

Abstract

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies’ cost-effectiveness. The patients’ age and fibrosis stage, assumed DAA treatment cost of €15,000/patient, and the Italian liver disease costs were used to evaluate quality-adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER) of policy 1 versus policy 2. To generalize the results, a European scenario analysis was performed, resampling the study population, using the mean European country-specific health states costs and mean treatment cost of €30,000. For the Italian base-case analysis, the cost-effective ICER obtained using policy 1 was €8,775/QALY. ICERs remained cost-effective in 94%-97% of the 10,000 probabilistic simulations. For the European treatment scenario the ICER obtained using policy 1 was €19,541.75/QALY. ICER was sensitive to variations in DAA costs, in the utility value of patients in fibrosis stages F0-F3 post–sustained virological response, and in the transition probabilities from F0 to F3. The ICERs decrease with decreasing DAA prices, becoming cost-saving for the base price (€15,000) discounts of at least 75% applied in patients with F0-F2 fibrosis. Conclusion: Extending hepatitis C virus treatment to patients in any fibrosis stage improves health outcomes and is cost-effective; cost-effectiveness significantly increases wh

Published
2017

13. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Author

Petta, S, Marzioni, M, Russo, P, Aghemo, A, Alberti, A, Ascione, A, Antinori, A, Bruno, R, Bruno, S, Chirianni, A, Gaeta, G, Giannini, E, Merli, M, Messina, V, Montilla, S, Perno, C, Puoti, M, Raimondo, G, Rendina, M, Silberstein, F, Villa, E, Zignego, A, Pani, L, Craxì, A, Fagiuoli, S, Gaeta, GB, Giannini, EG, Perno, CF, Silberstein, FC, Zignego, AL, FAGIUOLI, STEFANO, Petta, S, Marzioni, M, Russo, P, Aghemo, A, Alberti, A, Ascione, A, Antinori, A, Bruno, R, Bruno, S, Chirianni, A, Gaeta, G, Giannini, E, Merli, M, Messina, V, Montilla, S, Perno, C, Puoti, M, Raimondo, G, Rendina, M, Silberstein, F, Villa, E, Zignego, A, Pani, L, Craxì, A, Fagiuoli, S, Gaeta, GB, Giannini, EG, Perno, CF, Silberstein, FC, Zignego, AL, and FAGIUOLI, STEFANO

Abstract

Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) p

Published
2017

14. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

Author

Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M, Zignego AL, Romano M, Carrara M, Almasio PL, Azzola E, Nardone G, Benedetti A, Carosi G, Mazzotta F, Sagnelli E, Rizzetto M, for the AIFA Study Group, Italian Association for the Study of the Liver, Italian Society for Infectious, Tropical Diseases, Italian Association of Hospital Gastroenterologists, Italian Society of Gastroenterology, LOGUERCIO, Carmelina, Rosina, F, Tosti, Me, Borghesio, E, Masocco, M, Mele, A, Coppola, C, Milella, M, Borgia, G, Andreone, P, Koch, M, Zignego, Al, Romano, M, Carrara, M, Almasio, Pl, Azzola, E, Nardone, G, Benedetti, A, Carosi, G, Mazzotta, F, Sagnelli, E, Rizzetto, M, for the AIFA Study, Group, Italian Association for the Study of the, Liver, Italian Society for, Infectiou, Tropical, Disease, Italian Association of Hospital, Gastroenterologist, Italian Society of, Gastroenterology, and Loguercio, Carmelina

Published
2014

16. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

Author

GUARD C, Study Group, Hassanein, T, Bakalos, G, Ahlers, S, Shiffman, Ml, Tallarico, L, Reddy, Kr, Orlandini, A, Ferenci, P, Derbala, M, Coppola, C, Foster, Gr, Basho, J, Shabanaj, G, Harxhi, A, Debzi, N, Afredj, N, Guessab, N, Mahindad, N, Mahiou, H, Aissaoui, M, Al Qameesh, J, Al Ghandoor, Z, Assene, C, Bastens, B, Brixko, C, Cool, M, De Galocsy, C, Delwaide, J, George, C, Laukens, P, Lefebvre, V, Mulkay, Jp, Nevens, F, Servais, B, Van Vlierberghe, H, Horsmans, Y, Henrion, J, Sprengers, D, Michielsen, P, Bourgeois, S, Lasser, L, Langlet, P, Robaeys, G, Martinet, Jp, Warzee, P, Hoste, P, Reynaert, H, Juriens, I, Decaestecker, J, Van Der Meersch, F, Janssens, F, Ahmetagic, S, Verhaz, A, Bevanda, M, Calkic, L, Ibrahimpasic, N, Mesihovic, R, Mello, Ce, Ruiz, Fj, Martins Junior, E, Ferraz, Ml, Silva, G, Mendes, C, Lyra, A, Silva, Mh, Gomide, G, Fernandes, Jc, Pereira, P, Correa, Mc, Teixeira, R, Yousry, A, Hanno, A, Gabr, M, Omar, A, Esmat, G, Karatapanis, S, Nikolopoulou, V, Giannoulis, G, Manolakopoulos, S, Elefsiniotis, I, Drakoulis, C, Dimitroulopoulos, D, Kanatakis, S, Ketikoglou, I, Mimidis, K, Evgenidis, N, Akriviades, E, Vafiadi Zoubouli, I, Tsianos, E, Mela, M, Orfanou, E, Mousoulis, G, Karagiannis, I, Manesis, E, Varga, M, Nemesánszky, E, Fried, K, Schuller, J, Szalay, F, Lengyel, G, Tornai, I, Banyai, T, Lesch, M, Nagy, I, Gervain, J, Tusnadi, A, Schneider, F, Szentgyörgyi, L, Hunyady, B, Vincze, A, Tolvaj, G, Varkonyi, I, Makkai, E, Enyedi, J, Racz, I, Hausinger, P, Váczi, Z, Patai, Á, Ozsvár, Z, Lakner, L, Ribiczey, P, Bhalla, A, Somani, S, Luaia, R, Rao, P, Philip, M, Lawate, P, Nagral, A, Sood, A, Parikh, S, Merat, S, Nassiri Toosi, M, Alavian, Sm, Zali, Mr, Daryani, Ne, Drenaggi, D, Attili, Af, Bandiera, F, Bassi, P, Bellati, G, Bellantani, S, Brunetto, MAURIZIA ROSSANA, Bruno, S, Castelli, F, Castellacci, R, Cattelan, Am, Colombo, M, Craxi, A, D'Angelo, S, Colombo, S, Demelia, L, Di Perri, G, Di Giacomo, A, Ferrari, C, Francisci, D, Casinelli, K, Ganga, R, Costa, C, Mangia, A, Russo, Fp, Matarazzo, F, Mazzella, G, Mazzeo, M, Memoli, M, Montalbano, M, Montalto, G, Pieri, A, Passariello, N, Picciotto, A, Pietrangelo, A, Pirisi, M, Quirino, T, Raimondo, G, Rapaccini, Gl, Rizzardini, G, Rizzetto, M, Russello, M, Sabusco, G, Santantonio, T, Soardo, G, Amedea, A, Verucchi, G, Vinelli, F, Zignego, Al, Zuin, M, Ascione, A, Vinci, M, Pigozzi, Mg, Tundo, P, Saracco, Gm, Amoroso, P, Andreoni, M, Colletta, C, Erne, E, Megna, As, Biglino, A, Chiriaco, P, Foti, G, Spinzi, G, D'Amico, E, Paik, Sw, Ahn, Sh, Lee, Yn, Kim, Y, Yang, J, Han, Sy, Varghese, R, Al Gharabally, A, Askar, H, Sharara, A, Yaghi, C, Rached, Aa, Houmani, Z, Zaarour, F, Dohaibi, A, Ivanovski, L, Joksimovic, N, Abbas, Z, Memon, S, Mohsin, A, Masood, S, Hashmi, Z, Halota, W, Deron, Z, Mazur, W, Flisiak, R, Lipczynski, A, Musialik, J, Piekarska, A, Augustyniak, K, Baka Cwierz, B, Simon, K, Gietka, A, Berak, H, Sieklucki, J, Radowska, D, Szlauer, B, Piekos, T, Olszok, I, Jablkowski, M, Orszulak, G, Warakomska, I, Aleixo, Mj, Valente, C, Macedo, G, Sarmento Castro, R, Roxo, F, Faria, T, Mansinho, K, Velez, J, Ramos, Jp, Guerreiro, H, Alberto, S, Monteverde, C, Serejo, F, Peixe, P, Malhado, J, Curescu, M, Streinu Cercel, A, Caruntu, F, Livia, H, Preotescu, L, Arama, V, Ancuta, I, Gheorghe, L, Stanciu, C, Trifan, A, Acalovschi, M, Andreica, V, Pascu, O, Lencu, M, Sporea, I, Olteanu, D, Ionita Radu, F, Fierbinteanu Braticevici, C, Motoc, A, Silaghi, R, Musat, M, Coman, F, Stan, M, Cijevschi, C, Miftode, E, Delic, D, Jesic, R, Nozic, D, Svorcan, P, Fabri, M, Konstantinovic, L, Pelemis, M, Jankovic, G, Todorovic, Z, Nagorni, A, Kupcova, V, Skladany, L, Szantova, M, Krkoska, D, Jarcuska, P, Schreter, I, Oltman, M, Bocakova, J, Bunganic, I, Holoman, J, Giguere, A, Abdou, A. M., Basic (bio-) Medical Sciences, Gastroenterology, Laboratory of Molecullar and Cellular Therapy, Liver Cell Biology, Michielsen, Peter, GUARD-C Study Group, Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahler, Georgios Bakalo, Tarek Hassanein, GUARD-C Study Group: [.., Davide Drenaggi, Adolfo Francesco Attili, Franco Bandiera, Paolo Bassi, Giorgio Bellati, Stefano Bellantani, Maurizia Brunetto, Savino Bruno, Francesco Castelli, Roberto Castellacci, Anna Maria Cattelan, Massimo Colombo, Antonio Craxi, Salvatore D'angelo, Silvia Colombo, Luigi Demelia, Giovanni Di Perri, Antonio Di Giacomo, Carlo Ferrari, Daniela Francisci, Katia Casinelli, Roberto Ganga, Chiara Costa, Alessandra Mangia, Francesco Paolo Russo, Filippo Matarazzo, Giuseppe Mazzella, Maurizio Mazzeo, Massimo Memoli, Marzia Montalbano, Giuseppe Montalto, Alessandro Pieri, Nicola Passariello, Antonio Picciotto, Antonello Pietrangelo, Mario Pirisi, Tiziana Quirino, Giovanni Raimondo, Gian Ludovico Rapaccini, Giuliano Rizzardini, Mario Rizzetto, Maurizio Russello, Giuseppe Sabusco, Teresa Santantonio, Giorgio Soardo, Alessandri Amedea, Gabriella Verucchi, Francesco Vinelli, Anna Linda Zignego, Massimo Zuin, Antonio Ascione, Maria Vinci, Maria Graziella Pigozzi, Paolo Tundo, Giorgio Maria Saracco, Pietro Amoroso, Massimo Andreoni, Cosimo Colletta, Elke Erne, Angelo Salomone Megna, Alberto Biglino, Piergiorgio Chiriaco, Giuseppe Foti, Giancarlo Spinzi, Emilio D'amico, …], Foster G.R., Coppola C., Derbala M., Ferenci P., Orlandini A., Reddy K.R., Tallarico L., Shiffman M.L., Ahlers S., Bakalos G., Hassanein T., Basho J., Shabanaj G., Harxhi A., Debzi N., Afredj N., Guessab N., Mahindad N., Mahiou H., Aissaoui M., Al Qameesh J., Al Ghandoor Z., Assene C., Bastens B., Brixko C., Cool M., De Galocsy C., Delwaide J., George C., Laukens P., Lefebvre V., Mulkay J.-P., Nevens F., Servais B., Van Vlierberghe H., Horsmans Y., Henrion J., Sprengers D., Michielsen P., Bourgeois S., Lasser L., Langlet P., Robaeys G., Martinet J.-P., Warzee P., Hoste P., Reynaert H., Juriens I., Decaestecker J., Van Der Meersch F., Janssens F., Ahmetagic S., Verhaz A., Bevanda M., Calkic L., Ibrahimpasic N., Mesihovic R., Mello C.E., Ruiz F.J., Junior E.M., Ferraz M.L., Silva G., Mendes C., Lyra A., Silva M.H., Gomide G., Fernandes J.C., Pereira P., Correa M.C., Teixeira R., Yousry A., Hanno A., Gabr M., Omar A., Esmat G., Karatapanis S., Nikolopoulou V., Giannoulis G., Manolakopoulos S., Elefsiniotis I., Drakoulis C., Dimitroulopoulos D., Kanatakis S., Ketikoglou I., Mimidis K., Evgenidis N., Akriviades E., Vafiadi-Zoubouli I., Tsianos E., Mela M., Orfanou E., Mousoulis G., Karagiannis I., Manesis E., Varga M., Nemesanszky E., Fried K., Schuller J., Szalay F., Lengyel G., Tornai I., Banyai T., Lesch M., Nagy I., Gervain J., Tusnadi A., Schneider F., Szentgyorgyi L., Hunyady B., Vincze A., Tolvaj G., Varkonyi I., Makkai E., Enyedi J., Racz I., Hausinger P., Vaczi Z., Patai A., Ozsvar Z., Lakner L., Ribiczey P., Bhalla A., Somani S., Luaia R., Rao P., Philip M., Lawate P., Nagral A., Sood A., Parikh S., Merat S., Nassiri-Toosi M., Alavian S.-M., Zali M.R., Daryani N.E., Drenaggi D., Attili A.F., Bandiera F., Bassi P., Bellati G., Bellantani S., Brunetto M., Bruno S., Castelli F., Castellacci R., Cattelan A.M., Colombo M., Craxi A., D'angelo S., Colombo S., Demelia L., Di Perri G., Di Giacomo A., Ferrari C., Francisci D., Casinelli K., Ganga R., Costa C., Mangia A., Russo F.P., Matarazzo F., Mazzella G., Mazzeo M., Memoli M., Montalbano M., Montalto G., Pieri A., Passariello N., Picciotto A., Pietrangelo A., Pirisi M., Quirino T., Raimondo G., Rapaccini G.L., Rizzardini G., Rizzetto M., Russello M., Sabusco G., Santantonio T., Soardo G., Amedea A., Verucchi G., Vinelli F., Zignego A.L., Zuin M., Ascione A., Vinci M., Pigozzi M.G., Tundo P., Saracco G.M., Amoroso P., Andreoni M., Colletta C., Erne E., Megna A.S., Biglino A., Chiriaco P., Foti G., Spinzi G., D'amico E., Paik S.W., Ahn S.-H., Lee Y.N., Kim Y., Yang J., Han S.Y., Varghese R., Al Gharabally A., Askar H., Sharara A., Yaghi C., Abou Rached A., Houmani Z., Zaarour F., Dohaibi A., Ivanovski L., Joksimovic N., Abbas Z., Memon S., Mohsin A., Masood S., Hashmi Z., Halota W., Deron Z., Mazur W., Flisiak R., Lipczynski A., Musialik J., Piekarska A., Augustyniak K., Baka-Cwierz B., Simon K., Gietka A., Berak H., Sieklucki J., Radowska D., Szlauer B., Piekos T., Olszok I., Jablkowski M., Orszulak G., Warakomska I., Aleixo M.J., Valente C., Macedo G., Sarmento-Castro R., Roxo F., Faria T., Mansinho K., Velez J., Ramos J.P., Guerreiro H., Alberto S., Monteverde C., Serejo F., Peixe P., Malhado J., Curescu M., Streinu-Cercel A., Caruntu F., Livia H., Preotescu L., Arama V., Ancuta I., Gheorghe L., Stanciu C., Trifan A., Acalovschi M., Andreica V., Pascu O., Lencu M., Sporea I., Olteanu D., Ionita-Radu F., Fierbinteanu-Braticevici C., Motoc A., Silaghi R., Musat M., Coman F., Stan M., Cijevschi C., Miftode E., Delic D., Jesic R., Nozic D., Svorcan P., Fabri M., Konstantinovic L., Pelemis M., Jankovic G., Todorovic Z., Nagorni A., Kupcova V., Skladany L., Szantova M., Krkoska D., Jarcuska P., Schreter I., Oltman M., Bocakova J., Bunganic I., Holoman J., Giguere A., Abdou A.M.S., UCL - SSS/IREC-Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN-Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie

Subjects
Genetics and Molecular Biology (all), Male, Chronic Hepatitis, Hepacivirus, Ribavirin/adverse effects, Asthenia/chemically induced, Polyethylene Glycol, Biochemistry, Polyethylene Glycols, Body Mass Index, Chronic Liver Disease, 0302 clinical medicine, Neutropenia/chemically induced, Interferon-alpha/adverse effects, Medicine, Chronic, lcsh:Science, Liver Diseases, virus diseases, Antiviral Agents/adverse effects, Cohort, Science & Technology - Other Topics, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Cohort study, Human, medicine.medical_specialty, Alpha interferon, Gastroenterology and Hepatology, Antiviral Agents, Microbiology, Dose-Response Relationship, 03 medical and health sciences, Pharmacotherapy, Hepatitis C, Chronic/drug therapy, Dose Prediction Methods, Drug Therapy, Anemia/chemically induced, Humans, Hemoglobin, Aged, Medicine and health sciences, Biochemistry, Genetics and Molecular Biology (all), Hepaciviru, Science & Technology, Dose-Response Relationship, Drug, Flaviviruses, lcsh:R, Organisms, Biology and Life Sciences, Proteins, medicine.disease, digestive system diseases, chemistry, Agricultural and Biological Sciences (all), Withholding Treatment, Asthenia, Immunology, Proportional Hazards Model, lcsh:Q, Human medicine, RNA viruses, Physiology, lcsh:Medicine, Peginterferon-alfa, Polyethylene Glycols/adverse effects, Adult, Anemia, Cohort Studies, Female, Hepatitis C, Chronic, Host-Pathogen Interactions, Interferon-alpha, Middle Aged, Neutropenia, Outcome Assessment (Health Care), Proportional Hazards Models, RNA, Viral, Recombinant Proteins, Ribavirin, Medicine (all), chemistry.chemical_compound, Outcome Assessment, Health Care, Medicine and Health Sciences, 030212 general & internal medicine, Viral, Pathology and laboratory medicine, Multidisciplinary, biology, Hepatitis C virus, Pharmaceutics, Hepatitis C, Hematology, Recombinant Protein, Outcome Assessment (Health Care)/methods, Medical microbiology, Host-Pathogen Interaction, Multidisciplinary Sciences, Physiological Parameters, Research Design, Combination, Viruses, Drug, Pathogens, Host-Pathogen Interactions/drug effects, Research Article, Clinical Research Design, Research and Analysis Methods, Internal medicine, Recombinant Proteins/adverse effects, RNA, Viral/blood, Antiviral Agent, business.industry, Body Weight, Hepacivirus/drug effects, Viral pathogens, biology.organism_classification, Hepatitis viruses, Microbial pathogens, RNA, Adverse Events, Cohort Studie, business
Abstract

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

Published
2015

17. Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins

Author

Quartuccio, L, Corazza, L, Ramos Casals, M, Retamozo, S, Ragab, Gm, Ferraccioli, G, Gremese, E, Tzioufas, A, Voulgarelis, M, Vassilopoulos, D, Koutsianas, C, Scarpato, S, Salvarani, Carlo, Guillevin, L, Terrier, B, Cacoub, P, Saccardo, F, Gabrielli, A, Fraticelli, P, Tomsic, M, Tavoni, A, Nishimoto, N, Filippini, D, Scaini, P, Zignego, Al, Ferri, Clodoveo, Sansonno, D, Monti, G, Pietrogrande, M, Galli, M, Bombardieri, S, and Vita, S. De

Published
2015

20. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

Author

De Vita, S, Quartuccio, L, Isola, M, Mazzaro, C, Scaini, P, Lenzi, M, Campanini, M, Naclerio, C, Tavoni, A, Pietrogrande, M, Ferri, C, Mascia, Mt, Masolini, P, Zabotti, A, Maset, M, Roccatello, D, Zignego, Al, Pioltelli, P, Gabrielli, A, Filippini, D, Perrella, O, Migliaresi, S, Galli, M, Bombardieri, Stefano, Monti, G., De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, and Monti G.

Subjects
rituximab, vasculiti, hemic and lymphatic diseases, cryoglobulinemic, macromolecular substances, cryoglobulinemia, vasculitis
Abstract

To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.

Published
2012

21. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2

Author

De Re, V, De Zorzi, M, Caggiari, L, Lauletta, G, Tornesello, ML, Fognani, E, Miorin, M, Racanelli, V, Quartuccio, L, Gragnani, L, Russi, S, Pavone, F, Ghersetti, M, Costa, EG, Casarin, P, Bomben, R, Mazzaro, C, Basaglia, G, Berretta, M, Vaccher, E, Izzo, F, Buonaguro, FM, De Vita, S, Zignego, AL, De Paoli, P, Dolcetti, R, De Re, V, De Zorzi, M, Caggiari, L, Lauletta, G, Tornesello, ML, Fognani, E, Miorin, M, Racanelli, V, Quartuccio, L, Gragnani, L, Russi, S, Pavone, F, Ghersetti, M, Costa, EG, Casarin, P, Bomben, R, Mazzaro, C, Basaglia, G, Berretta, M, Vaccher, E, Izzo, F, Buonaguro, FM, De Vita, S, Zignego, AL, De Paoli, P, and Dolcetti, R

Abstract

To explore the relationship between innate immunity and hepatitis C Virus (HCV) in determining the risk of cirrhosis (CIR), hepatocellular carcinoma (HCC), mixed cryoglobulinemia syndrome (MCS) and non-Hodgkin lymphoma (NHL), we investigated the impact of the toll-like receptor-2 (TLR2) and interleukin-28B (IL28B) genetic variants. TLR2 -174 del variant was associated with TLR2 expression and with specific downstream molecules that drive the expression of different interleukins; rs12979860 Il28B was important in response to interferon-treatment and in spontaneous clearance of HCV. The risk for liver and lymphoproliferative diseases in HCV progression was clarified by stratifying 862 HCV-positive patients into groups based on liver (CIR, HCC) and lymphoproliferative HCV-related diseases (MCS, NHL) and compared with chronic HCV (CHC) infection. Analysis of TLR2-IL28B haplotypes showed an association of wild type haplotype with the lymphoproliferative diseases (OR 1.77, p = 0.029) and a slight increase in HCV viral load (HR 1.38, p = 0.054). Wild type haplotype (TLR2 ins/ins- IL28B C/C) was also found associated with older age in patients with an hepatic diseases (in CIR and in HCC p = 0.038 and p = 0.020, respectively) supporting an effect of innate immunity in the liver disease progression. TLR2 and IL28B polymorphisms in combination showed a role in the control of HCV viral load and different HCV disease progression.

Published
2016

22. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Author

Foster, GR, Chayama, K, Chuang, W-L, Fainboim, H, Farkkila, M, Gadano, A, Gaeta, GB, Hezode, C, Inada, Y, Heo, J, Kumada, H, Lu, S-N, Marcellin, P, Moreno, C, Roberts, SK, Strasser, SI, Thompson, AJ, Toyota, J, Paik, SW, Vierling, JM, Zignego, AL, Cohen, D, McPhee, F, Wind-Rotolo, M, Srinivasan, S, Hruska, M, Myler, H, Portsmouth, SD, Foster, GR, Chayama, K, Chuang, W-L, Fainboim, H, Farkkila, M, Gadano, A, Gaeta, GB, Hezode, C, Inada, Y, Heo, J, Kumada, H, Lu, S-N, Marcellin, P, Moreno, C, Roberts, SK, Strasser, SI, Thompson, AJ, Toyota, J, Paik, SW, Vierling, JM, Zignego, AL, Cohen, D, McPhee, F, Wind-Rotolo, M, Srinivasan, S, Hruska, M, Myler, H, and Portsmouth, SD

Abstract

BACKGROUND AND PURPOSE: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. METHODS: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). RESULTS: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. CONCLUSION: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV.

Published
2016

26. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

Author

Rosina, F, Tosti, Me, Borghesio, E, Masocco, M, Mele, A, Coppola, C, Milella, M, Borgia, G, Andreone, P, Koch, M, Zignego, Al, Romano, M, Carrara, M, Almasio, Pl, Azzola, E, Nardone, G, Benedetti, A, Carosi, G, Mazzotta, F, Sagnelli, E, Rizzetto, M, AIFA Study Group, Italian Association for the Study of the Liver, Italian Society for Infectious, Tropical, Diseases, Italian Association of Hospital Gastroenterologists, Italian Society of Gastroenterology, Italian Association for the Study of the Liver AISF, Tropical Diseases SIMIT, Italian Association of Hospital Gastroenterologists AIGO, and Contini, Carlo

Subjects
Peg-interferon/ribavirin, therapy, chronic hepatitis C, hepatitis C virus genotype cC, NO
Published
2014

28. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach

Author

Zignego AL, Ferri C, Caini P, Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection, PILERI, STEFANO, BIANCHI, FRANCESCO BIANCO, Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB., and Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection

Subjects
Porphyria Cutanea Tarda, Hepatitis C Virus, Lymphoma, B-Cell, Hepatitis C virus, Paraproteinemias, Lymphoproliferative disorders, medicine.disease_cause, Virus, Autoimmune Diseases, Interferon, Sicca syndrome, medicine, Humans, Porphyria cutanea tarda, Hepatology, business.industry, Gastroenterology, Lichen Planus, Hepatitis C, medicine.disease, Lymphoproliferative Disorders, Cryoglobulinemia, Immunology, Polyarthritis, business, medicine.drug
Abstract

Hepatitis C Virus is associated with a wide series of extrahepatic manifestations. Based on available data the link between the virus and some of these extrahepatic diseases is only suggested and needs further confirmation. Hepatitis C Virus-related lymphoproliferative disorders, whose prototype is mixed cryoglobulinaemia, represent the most closely related extrahepatic manifestations of Hepatitis C Virus. Other Hepatitis C Virus-associated disorders include nephropathies, thyreopathies, sicca syndrome, idiopathic pulmonary fibrosis, porphyria cutanea tarda, lichen planus, diabetes, chronic polyarthritis, cardiopathy and atherosclerosis. A pathogenetic link between Hepatitis C Virus and some extrahepatic manifestations was confirmed by their responsiveness to antiviral therapy, which is now deemed the first therapeutic option to consider. By contrast, there are diseases where treatment with interferon was ineffective or dangerous. The aim of the present paper is to outline the most recent evidence concerning extrahepatic disorders that are possibly associated with Hepatitis C Virus infection. Special emphasis will be given to discussion of the most appropriate clinical approaches to be adopted in order to diagnose, treat (possibly prevent) and follow-up extrahepathic diseases in patients with Hepatitis C Virus infection.

Published
2007

32. Validation of the classification criteria for cryoglobulinaemic vasculitis

Author

Quartuccio, L, Isola, M, Corazza, L, Ramos Casals, M, Retamozo, S, Ragab, Gm, Zoheir, Mn, El Menyawi, Ma, Salem, Mn, Sansonno, D, Ferraccioli, Gianfranco, Gremese, Elisa, Tzioufas, A, Voulgarelis, M, Vassilopoulos, D, Scarpato, S, Pipitone, N, Salvarani, C, Guillevin, L, Terrier, B, Cacoub, P, Filippini, D, Saccardo, F, Gabrielli, A, Fraticelli, P, Sebastiani, M, Tomsic, M, Tavoni, A, Mazzaro, C, Pioltelli, P, Nishimoto, N, Zignego, Al, Ferri, C, Monti, G, Pietrogrande, M, Bombardieri, S, Galli, M, De Vita, S., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Gremese, Elisa (ORCID:0000-0002-2248-1058), Quartuccio, L, Isola, M, Corazza, L, Ramos Casals, M, Retamozo, S, Ragab, Gm, Zoheir, Mn, El Menyawi, Ma, Salem, Mn, Sansonno, D, Ferraccioli, Gianfranco, Gremese, Elisa, Tzioufas, A, Voulgarelis, M, Vassilopoulos, D, Scarpato, S, Pipitone, N, Salvarani, C, Guillevin, L, Terrier, B, Cacoub, P, Filippini, D, Saccardo, F, Gabrielli, A, Fraticelli, P, Sebastiani, M, Tomsic, M, Tavoni, A, Mazzaro, C, Pioltelli, P, Nishimoto, N, Zignego, Al, Ferri, C, Monti, G, Pietrogrande, M, Bombardieri, S, Galli, M, De Vita, S., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), and Gremese, Elisa (ORCID:0000-0002-2248-1058)

Abstract

The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV).

Published
2014

33. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/Hepatitis C virus coinfected patients

Author

Raimondo, G, Brunetto, Mr, Pontisso, P, Smedile, A, Maina, Am, Saitta, C, Squadrito, G, AND ASSOCIAZIONE ITALIANA STUDIO FEGATO AISF COOPERATIVE GROUP OLIVERO A, TONO N., Rosina, F, Sartori, M, Colombo, M, Lampertico, P, Fargion, S, Rossini, A, Fattovich, Giovanna, Ruvoletto, Mg, Villano, M, Croc, L, Picciotto, A, Ferrari, C, Missale, G, Zignego, Al, Moscato, G, Toti, M, Levriero, M, Puoti, C, Caporaso, N, Morisco, F, Gaeta, Gb, Piccinino, F, Sagnelli, E, Persico, M, Andriulli, A, Niro, Ga, Dentico, P, Pastore, G, Santantonio, T, Crax, A, DI MARCO, V, Cacopardo, B, Bruno, S, Smedile, V, Aiello, A, Brancatelli, S, Costantino, L, Pollicino, T, and Raffa, G.

Subjects
hepatitis B, hepatitis c, coinfection, virological profile
Published
2006

35. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis

Author

Quartuccio, L, Isola, M, Corazza, L, Maset, M, Monti, G, Gabrielli, A, Tzioufas, Ag, Ferri, C, Ferraccioli, Gianfranco, Ramos Casals, M, Voulgarelis, M, Lenzi, M, Mascia, Mt, Sansonno, D, Cacoub, P, Tomsic, M, Tavoni, A, Pietrogrande, M, Zignego, Al, Scarpato, S, Pioltelli, P, Steinfeld, S, Lamprecht, P, Galli, M, Bombardieri, S, De Vita, S., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Quartuccio, L, Isola, M, Corazza, L, Maset, M, Monti, G, Gabrielli, A, Tzioufas, Ag, Ferri, C, Ferraccioli, Gianfranco, Ramos Casals, M, Voulgarelis, M, Lenzi, M, Mascia, Mt, Sansonno, D, Cacoub, P, Tomsic, M, Tavoni, A, Pietrogrande, M, Zignego, Al, Scarpato, S, Pioltelli, P, Steinfeld, S, Lamprecht, P, Galli, M, Bombardieri, S, De Vita, S., and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

Abstract

Cryoglobulinaemic vasculitis (CV) is often related to hepatitis C virus (HCV) infection, but it can develop in other diseases (e.g. other infections, connective tissue diseases, malignancies) in the absence of HCV infection. A comparison of the performance of the recently published classification criteria for the CV was made between HCV-positive and HCV negative patients with serum cryoglobulins.

Published
2012

37. Preliminary classification criteria for the cryoglobulinaemic vasculitis

Author

De Vita, S, Soldano, F, Isola, M, Monti, G, Gabrielli, Angelo, Tzioufas, A, Ferri, C, Ferraccioli, Gianfranco, Quartuccio, L, Corazza, L, De Marchi, Giovanni, Ramos Casals, M, Voulgarelis, M, Lenzi, M, Saccardo, F, Fraticelli, P, Mascia, Mt, Sansonno, D, Cacoub, P, Tomsic, M, Tavoni, A, Pietrogrande, M, Zignego, Al, Scarpato, S, Mazzaro, C, Pioltelli, P, Steinfeld, S, Lamprecht, P, Bombardieri, S, Galli, Marco, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Galli, Marco (ORCID:0000-0003-0254-6448), De Vita, S, Soldano, F, Isola, M, Monti, G, Gabrielli, Angelo, Tzioufas, A, Ferri, C, Ferraccioli, Gianfranco, Quartuccio, L, Corazza, L, De Marchi, Giovanni, Ramos Casals, M, Voulgarelis, M, Lenzi, M, Saccardo, F, Fraticelli, P, Mascia, Mt, Sansonno, D, Cacoub, P, Tomsic, M, Tavoni, A, Pietrogrande, M, Zignego, Al, Scarpato, S, Mazzaro, C, Pioltelli, P, Steinfeld, S, Lamprecht, P, Bombardieri, S, Galli, Marco, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), and Galli, Marco (ORCID:0000-0003-0254-6448)

Abstract

To develop preliminary classification criteria for the cryoglobulinaemic syndrome or cryoglobulinaemic vasculitis (CV).

Published
2011

38. Hepatitis-C-virus infection and cancer

Author

Ferri, Clodoveo, La Civita, L, Zignego, Al, and Pasero, G.

Subjects
Carcinoma, Hepatocellular, Hepatitis C virus, Lymphoma, Non-Hodgkin, Liver Neoplasms, cancer, Humans, lymphoma, hepatocellular carcinoma, Hepatitis C, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoproliferative Disorders
Published
1997

39. Hepatitis C virus and lymphoproliferative disorders

Author

Ferri, Clodoveo, La Civita, L, Caracciolo, F, Bellesi, G, and Zignego, Al

Subjects
Hepatitis C virus, lymphoproliferative disorders, lymphoma, Humans, Hepacivirus, Lymphoproliferative Disorders
Published
1996

Catalog

Books, media, physical & digital resources
See catalog results